Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 15Lymphoma, Large B-Cell, Diffuse 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Prostatic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Melanoma 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Plasmablastic Lymphoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Myeloid, Accelerated Phase 1HTLV-I Infections 1Down Syndrome 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Blast Crisis 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 23fludarabine 14Rituximab 14Specimen Handling 8Magnetic Resonance Spectroscopy 7Doxorubicin 7pirtobrutinib 6Vincristine 6Prednisone 6zanubrutinib 4polatuzumab vedotin 4obinutuzumab 4Nivolumab 4Etoposide 4Dexamethasone 4Biopsy 4tazemetostat 3tafasitamab 3pembrolizumab 3ibrutinib 3glofitamab 3fludarabine phosphate 3acalabrutinib 3Immunotherapy, Adoptive 3Bendamustine Hydrochloride 3venetoclax 2pomalidomide 2etoposide phosphate 2cemiplimab 2Prednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × deltacortene × 90 days × Clear all
NCT07097363 2026-04-23

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Recruiting
18 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡